# ProSight (Weihe five-cancer test in a screening population)

Source: https://onco.cc/trials/prosight-mced/  
OnCo record `prosight-mced` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Chinese study that gave about 2,500 people without symptoms a blood test for lung, bowel, liver, stomach and gullet cancer.

## Summary

ProSight (NCT06790355) is a single-arm interventional study sponsored by Shanghai Weihe Medical Laboratory Co., Ltd with Fudan University. It evaluated the feasibility of a blood test designed to detect lung, colorectal, liver, gastric and oesophageal cancer, which gives a binary result and predicts the signal origin.

The registry record, read on 29 October 2026, gives its status as completed, with 2,527 participants enrolled, a start on 1 March 2025 and primary completion on 31 August 2026.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-10-29
- Also known as: ProSight
- Registry id: NCT06790355
- Phase: not-applicable
- Setting: Adults without symptoms at four Chinese centres, given a blood test for five cancers alongside usual screening with diagnostic work-up of positives
- Sponsor: Shanghai Weihe Medical Laboratory Co., Ltd. with Fudan University
- Enrolled: 2527

## Sources

- ClinicalTrials.gov NCT06790355: https://clinicaltrials.gov/study/NCT06790355

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)

---
JSON: https://onco.cc/api/v1/entities/prosight-mced.json